Ikarian Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Ikarian Capital’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96M	Hold	31,166	–	–	0.21%	89
2026 Q1	$2.19M	Hold	31,166	–	–	0.18%	97
2025 Q4	$2.55M	Sell	31,166 -42,453	-58%	-$3.17M	0.2%	91
2025 Q3	$4.38M	Sell	73,619 -122,917	-63%	-$6.05M	0.44%	61
2025 Q2	$7.96M	Sell	196,536 -288,485	-59%	-$13M	1.53%	22
2025 Q1	$24.9M	Sell	485,021 -122,668	-20%	-$6.06M	3.07%	4
2024 Q4	$33.6M	Sell	607,689 -422,588	-41%	-$19.2M	4.58%	4
2024 Q3	$33.9M	Buy	1,030,277 +230,000	+29%	+$6.46M	4.73%	5
2024 Q2	$21.8M	Buy	800,277 +90,000	+13%	+$3.03M	3.79%	6
2024 Q1	$25.8M	Buy	710,277 +191,758	+37%	+$5.64M	2.83%	4
2023 Q4	$10.5M	Hold	518,519	–	–	0.98%	33
2023 Q3	$9.21M	Buy	+518,519	New	+$9.18M	1.11%	27

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital's TARS Position: Q2 2026 in Review

Ikarian Capital held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 31,166 shares worth $1.96M. The position accounts for 0.21% of the portfolio, ranked #89.

Ikarian Capital first reported a position in TARS in Q3 2023 and has held it in 12 quarters since. The position peaked at $33.9M in Q3 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Ikarian Capital held 31,166 shares of Tarsus Pharmaceuticals worth $1.96M as of Q2 2026.
Ikarian Capital left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
Tarsus Pharmaceuticals made up 0.21% of Ikarian Capital's portfolio in Q2 2026, its #89 holding.
Ikarian Capital first reported a position in Tarsus Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Ikarian Capital's Tarsus Pharmaceuticals position peaked at $33.9M in Q3 2024.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.